Searchable abstracts of presentations at key conferences in endocrinology

ea0050p251 | Neoplasia, Cancer and Late Effects | SFEBES2017

Endocrinopathies are a frequent Consequence of Immune Checkpoint Inhibitor Therapy, with a Low Recovery Rate of both Thyroid and Pituitary Dysfunction

McGowan Anne , Weatherby Tom , Powlson Andrew , Parkinson Christine , Chatterjee Krishna , Corrie Pippa , Moran Carla

Background: Immune checkpoint (CTLA-4, PD-1) inhibitors are increasingly used to treat cancers including advanced melanoma. Although endocrine immune related adverse events (IRAEs) are now well reported, the frequency and type of thyroid and pituitary dysfunction reported varies considerably, with hypophysitis after CTLA-4 inhibitors reported in 2–16%, and thyroid dysfunction after PD-1 inhibitors in 2–39%. In addition, recove...

ea0050p266 | Neuroendocrinology and Pituitary | SFEBES2017

Patterns of recurrence, response to treatment and mortality in patients with malignant phaeochromocytomas and paragangliomas. – a single centre experience

Abdel-Aziz Tarek , Chung Teng-Teng , Bomanji Jamshed , Gaze Mark , Kurzawinski Tom

Introduction: Histology is a poor predictor of the malignant potential of phaeochromocytomas and paragangliomas (PPGL) and only the presence of distant metastasis confirms malignancy. This study reviews patterns of recurrence, treatment and mortality in patients with malignant PPGL presenting to our department at UCLH over 30 years.Materials and Methods: In our series of 128 patients with PPGL, 26 (20%) with maligna...

ea0050oc1.2 | Early Career Oral Communications | SFEBES2017

Co-administration of 5α-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids

Marjot Tom , Othonos Nantia , Woods Conor , Hazlehurst Jonathan , Moolla Ahmad , Hodson Leanne , Tomlinson Jeremy

Glucocorticoids (GC) are commonly prescribed and their use is associated with adverse metabolic side effects. 5a-reductase (5aR) inhibitors are also frequently prescribed mainly for their ability to inhibit the conversion of testosterone to dihydrotestosterone. However, they also have a role to inactivate and clear GCs. We hypothesised that 5aR inhibitors have the potential to exacerbate the adverse metabolic effects of GCs. We conducted a prospective, randomised, study in 19 ...

ea0050p206 | Diabetes and Cardiovascular | SFEBES2017

The impact of a dedicated metabolic hepatology clinic for the treatment of non-alcoholic fatty liver disease

Motohashi Kenzo , Moolla Ahmad , Marjot Tom , Ainsworth Mark , Tomlinson Jeremy , Cobbold Jeremy

Introduction: Non-Alcoholic Fatty Liver Disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is tightly associated with insulin resistance and type 2 diabetes (T2DM), both risk factors for disease progression, liver failure and cardiovascular complications. A multidisciplinary approach involving hepatologists and diabetologists working alongside allied health professionals is thus advocated for the management of NAFLD. Interv...

ea0050p251 | Neoplasia, Cancer and Late Effects | SFEBES2017

Endocrinopathies are a frequent Consequence of Immune Checkpoint Inhibitor Therapy, with a Low Recovery Rate of both Thyroid and Pituitary Dysfunction

McGowan Anne , Weatherby Tom , Powlson Andrew , Parkinson Christine , Chatterjee Krishna , Corrie Pippa , Moran Carla

Background: Immune checkpoint (CTLA-4, PD-1) inhibitors are increasingly used to treat cancers including advanced melanoma. Although endocrine immune related adverse events (IRAEs) are now well reported, the frequency and type of thyroid and pituitary dysfunction reported varies considerably, with hypophysitis after CTLA-4 inhibitors reported in 2–16%, and thyroid dysfunction after PD-1 inhibitors in 2–39%. In addition, recove...

ea0050p266 | Neuroendocrinology and Pituitary | SFEBES2017

Patterns of recurrence, response to treatment and mortality in patients with malignant phaeochromocytomas and paragangliomas. – a single centre experience

Abdel-Aziz Tarek , Chung Teng-Teng , Bomanji Jamshed , Gaze Mark , Kurzawinski Tom

Introduction: Histology is a poor predictor of the malignant potential of phaeochromocytomas and paragangliomas (PPGL) and only the presence of distant metastasis confirms malignancy. This study reviews patterns of recurrence, treatment and mortality in patients with malignant PPGL presenting to our department at UCLH over 30 years.Materials and Methods: In our series of 128 patients with PPGL, 26 (20%) with maligna...

ea0086oc1.5 | Bone and Calcium | SFEBES2022

Can pre-operative treatment with intravenous bisphosphonates or cinacalcet have an effect on intra-operative parathyroid hormone measurements?

Wijewickrama Piyumi S A , Chung Teng-Teng , Abdel-Aziz Tarek E , Kurzawinski Tom R

Introduction: Primary hyperparathyroidism is a common endocrine disorder, surgery is curative. Patients with severe hypercalcemia receive cinacalcet or intravenous bisphosphonates as bridging. Intra-operative-parathyroid-hormone (IOPTH) measurement improves surgical accuracy. Bisphosphonates may increase PTH, while cinacalcet reduces it. The main aim was to assess the effect of zoledronate and cinacalcet on IOPTH.Method: Patients over 15-yo who underwent...

ea0086p275 | Reproductive Endocrinology | SFEBES2022

Follicle Sizes That are Most Likely to Yield Oocytes During In Vitro Fertilisation (IVF) Treatment

Alhamwi Toulin , Abbara Ali , Hanassab Simon , Comninos Alexander , Kelsey Tom , Salim Rehan , Heinis Thomas , Dhillo Waljit

Background: Infertility affects 1 in 6 couples causing devastating psychological impact. In vitro fertilisation (IVF) treatment can aid couples to conceive, but personalisation of treatment is needed to optimise patient outcomes. Machine learning can aid in the analysis of large complex datasets such as those encountered during IVF treatment. One example is in determining the optimal follicle size on the day of trigger to maximise the number of oocytes collected. Both follicle...